 To determine whether 18FFES can predict clinical benefit defined as complete response, partial response and stable disease 6 months to fulvestrant 250 mg IM q 28 days in post-menopausal women with recurrent or metastatic ER breast cancer who are candidates for further hormonal therapy. 